Diaceutics PLC (AIM: DXRX), the Belfast-headquartered diagnostic intelligence and engagement company, has disclosed that three persons discharging managerial responsibilities (PDMRs) purchased ordinary shares on 29 October 2026 under the company's Share Incentive Plan (SIP) schemes. Chief Growth Officer Susanne Munksted, Chief Customer Officer Jordan Clark, and Chief Financial Officer Nick Roberts each acquired shares at 203.8p on the AIM Market of the London Stock Exchange. The company matched each purchase with an equivalent conditional share award on a 1:1 basis, and separately confirmed that total shares in issue now stand at 85,291,958.

Key Points

  • Diaceutics PLC (AIM: DXRX) — diagnostic intelligence and engagement company operating across the UK, US and globally
  • Three PDMRs purchased ordinary shares at 203.8p on 29 October 2026 under the UK and Global Share Incentive Plan schemes
  • Munksted acquired 71 shares; Clark and Roberts each acquired 74 shares; all purchases matched 1:1 with conditional share awards at nil cost
  • Investors should watch for further monthly SIP purchases and any subsequent changes to total voting rights

PDMR Share Purchases at 203.8p Under Diaceutics' UK and Global SIP Schemes

The announcement states that Global Shares Trustees (UK) Limited and Zedra Trust Company (Guernsey) Limited, acting as trustees of the Global Diaceutics plc 2020 Employee Benefit Trust, executed the purchases on behalf of the three PDMRs. Susanne Munksted, in her capacity as Chief Growth Officer, acquired 71 ordinary shares of £0.002 each. Jordan Clark, Chief Customer Officer, and Nick Roberts, Chief Financial Officer, each purchased 74 shares. All transactions were conducted at 203.8p per share on the AIM Market. The announcement notes these purchases will continue on a monthly basis until further notice, reflecting the ongoing, non-discretionary nature of the SIP scheme.

Diaceutics Issues 3,896 New Shares to UK Trust to Settle Matched SIP Awards

In connection with the SIP transactions, Diaceutics confirmed it issued 3,896 new ordinary shares on 3 November 2026 to the UK Trust to settle matched share awards for UK PDMR participants and all other UK SIP scheme participants. These newly issued shares fall within the block listing of 1,500,000 shares that was admitted to AIM following an application made on 2 October 2023. The UK Trust will hold the matched shares on behalf of participants until they vest in accordance with the UK scheme rules. The matched awards were granted at nil cost, representing a direct benefit to participating employees upon eventual vesting.

Total Diaceutics Shares in Issue Rise to 85,291,958 Following September Option Exercises

The announcement also confirms that 53,810 shares were allotted during the period since the last Total Voting Rights announcement on 6 October 2026, to settle employee share option exercises during September 2026. Combined with the SIP-related issuances, the total number of Diaceutics ordinary shares in issue now stands at 85,291,958. The company has stated that this figure should be used by shareholders as the denominator when calculating whether they are required to notify an interest or change in interest under the FCA's Disclosure Guidance and Transparency Rules.

Diaceutics' Precision Diagnostics Model and Pharma Partnerships Underpin PDMR Participation

Founded in 2005, Diaceutics describes its mission as redefining commercialisation for diagnostic-driven therapies, aiming to ensure every eligible patient is found, diagnosed, and treated appropriately. The company works with 21 of the top 30 pharmaceutical companies globally, with supported therapies said to touch 1 in 10 American lives. Its revenue model combines diagnostic intelligence, expert insight, and targeted engagement services for biopharma clients. Ongoing PDMR participation in the SIP schemes may indicate continued alignment between senior management and shareholder interests, though investors will note that SIP purchases are structured as non-discretionary, ongoing monthly transactions.